Navigation Links
Atritech Completes $30 Million Financing
Date:3/26/2009

Company scheduled to announce PROTECT AF results on March 28th at ACC.

MINNEAPOLIS, March 26 /PRNewswire/ -- Atritech, Inc. a clinical stage medical device company, announced today that it has completed a $30 million round of financing. Thomas, McNerney & Partners led the round along with a substantial investment from Split Rock Partners and insider investments from Prism Ventures, Tullis-Dickerson and Vector Group. Over the past 3 years, the Company has raised approximately $75 million in capital.

With this new funding, the Company will complete the Food and Drug Administration (FDA) review of the PROTECT AF clinical trial results along with the commercial launch of the WATCHMAN(R) LAA Closure Technology in Europe. The PROTECT AF clinical trial evaluates the WATCHMAN device versus the current standard of care, warfarin, in patients with atrial fibrillation. In August of 2008, Atritech announced the filing of its Pre-Market Approval Application (PMA) to the FDA. The Company will present the PROTECT AF results to the FDA's Circulatory System Devices Panel on April 23, 2009. The WATCHMAN device continues to be implanted in a Continued Access Registry (CAP) while the product is under review at the FDA. To date over 110 devices have been implanted in CAP at approximately 20 sites in the U.S. and Europe.

Atritech's WATCHMAN device is designed to keep harmful sized blood clots from entering a patient's blood stream, potentially causing a stroke. Patients with AF (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a greater risk of having a stroke. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions causing many patients to stop taking them. The WATCHMAN device may be an effective alternative for patients w
'/>"/>

SOURCE Atritech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Completes Tender Offer for Genentech
2. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
3. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
4. Sangart, Inc. Completes Series F Funding Round
5. Cardium Completes $3.5 Million Credit Facility
6. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
7. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
8. CIRM Completes Briefing Visit to Stemedica Cell Technologies
9. INVO Bioscience Completes Reverse Merger
10. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
11. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Brook, NY (PRWEB) August 01, 2014 ... @APDN), a provider of DNA-based anti-counterfeiting technology and product ... August 12, 2014 to discuss its fiscal third quarter ... filed with the SEC by the end of the ... DNA Sciences, Inc. management will host a conference call ...
(Date:8/1/2014)... DUBLIN , Aug. 1, 2014 ... of the "The World Market for Flow ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... instruments that are now an important component of ... advanced diagnostic instruments for cancer diagnostics, but their ...
(Date:8/1/2014)... 1. 2014 As one of the 10 ... Annual Meeting & Clinical Lab Expo is the place ... are introduced to the healthcare world. This year, many ... exhibitors will include the latest diagnostic technology in the ... smartphones and biosensors have enabled the development of "labs-on-a-chip" ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 One ... the rise of personalized medicine, which is the practice ... medical treatments to a patient,s individual biology. Personalized diagnostics—laboratory ... a major role in the lab,s future. This fall, ... will feature the latest science in this exciting field ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3The World Market for Flow Cytometry in IVD Applications 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:8/1/2014)... -- Modern humans appear in the fossil record about ... years ago that making art and advanced tools became ... in the journal Current Anthropology finds that ... of testosterone levels at around the same time that ... technological innovation, making art and rapid cultural exchange probably ...
(Date:8/1/2014)... what causes them at the molecular level is even ... created the most detailed map to date of a ... diseases, such as age-related macular degeneration. The high-resolution molecular ... supplies blood and oxygen to the outer retina, itself ... of proteins in different areas of the choroid, the ...
(Date:8/1/2014)... the most diverse families in the ocean today -- ... originated more than 400 million years ago in the ... of its modern members. This Geology study ... online on 25 July 2014, tracks the remarkable evolutionary ... At is origin, the Lucinidae family remained at very ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2A map for eye disease 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... which cancer cells travel from a tumor site and proliferate ... to cancer patients. According to the National Cancer Institute, most ... Virtually all types of cancer can spread to other parts ... are entrenched in the brain, patients typically have only a ...
... the sensitivity of Australia,s species and ecosystems to climate ... about biodiversity conservation. ,Climate change is likely to ... 2030, lead researcher, CSIRO,s Dr Michael Dunlop said.,By 2070, ... and widespread. Many of the environments our plants and ...
... Researchers at the National Institute of Standards and Technology ... candidate refrigerant fluids with low "global warming potential" (GWP) ... for many decades as well as other desirable ... the most extensive systematic search for a new class ...
Cached Biology News:Fighting melanoma's attraction to the brain 2Major changes needed to protect Australia's species and ecosystems 2New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2
... The S. pombe Whole Genome ... location analysis of yeast (S. pombe) ... immunoprecipitation (ChIP) with Agilent DNA microarrays. ... reliable binding data with greater true ...
... genomes has allowed the development of the ... The S. enterica Typhimurium (strain LT2) genome ... 4,440 ORFs) and a plasmid, pSLT (93,939 ... have been designed to amplify all putative ...
... own microplate stacker system, offers fast and ... host devices:, , Ultra Evolution , SAFIRE ... and SpectraFluor Plus , LS Series of ... supporting a wide range of detection and ...
... LabX light balance makes your life easier. It ... acquisition and management for one balance. *Instruments supported: ... TOLEDO AX, MX, UMX, AG, XS, XP, PR, SR, ... balances *Job management: ...
Biology Products: